Archive · 18 Dec 2025
Eli Lilly's Obesity Pill Maintains Weight Loss
Eli Lilly has a new pill called orforglipron that helps people keep off the weight they lost using injections like Wegovy and Zepbound.
They tested it on over 300 people who had been using these injections for a long time.
The people who switched to the pill regained only a little weight, about 2 pounds from Wegovy and 11 pounds from Zepbound.
The pill is easier to take because it doesn't need injections and has fewer side effects.
Eli Lilly has asked the FDA to approve it, and if approved, it could be a big help for people with obesity who want an easier way to maintain their weight loss.
Eli Lilly's obesity pill orforglipron helps patients maintain weight loss after switching from injectable treatments like Wegovy and Zepbound.
The pill regained about 2 pounds from Wegovy and 11 pounds from Zepbound in a 52-week trial.
Eli Lilly has submitted an application to the FDA for approval, with a priority review voucher granted in November.
The pill offers a needle-free, convenient option for long-term weight loss maintenance with fewer side effects.
Full trial results will be presented at a medical conference and published in a peer-reviewed journal next year.
- Who
- Eli Lilly
- What
- Obesity pill orforglipron maintains weight loss after switching from injectable treatments
- When
- December 18, 2024
- Where
- United States
- Why
- To offer a convenient, needle-free maintenance treatment for obesity
- Drug Name
- Orforglipron
- Company
- Eli Lilly
- Trial Name
- ATTAIN-MAINTAIN
- Trial Duration
- 52 weeks
- Weight Regain from Wegovy
- 2 pounds
- Weight Regain from Zepbound
- 11 pounds
- Common Side Effects
- Mild to moderate gastrointestinal issues
- FDA Review Status
- Priority review voucher granted